Comment
doi: 10.1158/1940-6207.CAPR-11-0048.
The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples
Affiliations
- PMID: 21372028
- DOI: 10.1158/1940-6207.CAPR-11-0048
Item in Clipboard
Comment
The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples
Cancer Prev Res (Phila).
2011 Mar.
Free article
Abstract
This perspective discusses reports by Cramer and colleagues (beginning on page 365 in this issue of the journal) and Zhu and colleagues (beginning on page 375), which provide the first systematic and reliable comparison of a large number of candidate biomarkers for the early detection of ovarian cancer in a sample set well-suited for this purpose. This research has important implications for the future design of cancer biomarker studies.
Comment on
-
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195. Cancer Prev Res (Phila). 2011. PMID: 21372036 Free PMC article.
-
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193. Cancer Prev Res (Phila). 2011. PMID: 21372037 Free PMC article.
Similar articles
-
Challenges related to developing serum-based biomarkers for early ovarian cancer detection.Cancer Prev Res (Phila). 2011 Mar;4(3):303-6. doi: 10.1158/1940-6207.CAPR-11-0053. Cancer Prev Res (Phila). 2011. PMID: 21372029 Free PMC article.
-
Personalizing CA125 levels for ovarian cancer screening.Cancer Prev Res (Phila). 2011 Sep;4(9):1356-9. doi: 10.1158/1940-6207.CAPR-11-0378. Cancer Prev Res (Phila). 2011. PMID: 21893498
-
Ovarian Cancer Biomarkers: Moving Forward in Early Detection.Adv Exp Med Biol. 2020;1219:355-363. doi: 10.1007/978-3-030-34025-4_18. Adv Exp Med Biol. 2020. PMID: 32130708 Review.
-
E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.BMC Cancer. 2010 Feb 24;10:64. doi: 10.1186/1471-2407-10-64. BMC Cancer. 2010. PMID: 20181230 Free PMC article.
-
Protein biomarkers of ovarian cancer: the forest and the trees.Future Oncol. 2012 Jan;8(1):55-71. doi: 10.2217/fon.11.135. Future Oncol. 2012. PMID: 22149035 Free PMC article. Review.
Cited by
-
A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum.Int J Mol Sci. 2012 Oct 22;13(10):13587-604. doi: 10.3390/ijms131013587. Int J Mol Sci. 2012. PMID: 23202969 Free PMC article.
-
Ovarian cancer screening--current status, future directions.Gynecol Oncol. 2014 Feb;132(2):490-5. doi: 10.1016/j.ygyno.2013.11.030. Epub 2013 Dec 3. Gynecol Oncol. 2014. PMID: 24316306 Free PMC article. Review.
-
Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.Cancers (Basel). 2020 Aug 27;12(9):2428. doi: 10.3390/cancers12092428. Cancers (Basel). 2020. PMID: 32867043 Free PMC article. Review.
-
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.Mol Cancer. 2014 May 29;13:129. doi: 10.1186/1476-4598-13-129. Mol Cancer. 2014. PMID: 24886523 Free PMC article. Review.
-
Top-Down Proteomics of Human Saliva, Analyzed with Logistic Regression and Machine Learning Methods, Reveal Molecular Signatures of Ovarian Cancer.Int J Mol Sci. 2023 Oct 28;24(21):15716. doi: 10.3390/ijms242115716. Int J Mol Sci. 2023. PMID: 37958700 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
